
From: DS [REDACTED]
Sent: Tuesday, June 25, 2013 6:59 PM
To: Jeffrey Epstein
Subject: Fwd: Immodulon
Attachments: Immodulon NewsletterJan2013.pdf; Untitled attachment 00064.htm

Begin forwarded message:

From: Robert Pfeiffer <[REDACTED]>
Date: 24 June 2013 12:51:27 CEST
To: "d [REDACTED]"
Subject: FW: Immodulon

From: Charles Akle
Sent: Wednesday, June 19, 2013 1:07:58 PM
To: Robert Pfeiffer
Cc: Bilyard Kevin
Subject: Immodulon

Dear Robert

We promised some feedback after our trip and the fact=it has taken a few days shows how well it went. The easiest thing is to cop= what I have said to Anthony Bolton and our other shareholders:<=p>

Just to let you have some Breaking News as the BBC=would say! We have had a superb trip to Phoenix to visit Dr Dan von Hoff - h= is as I am sure you know the Key Opinion Leader for pancreatic cancer and h= just published the data from the Gem/Abraxane study which has helped Celgene shares rise nicely! I am su=e I gave you a copy of the TIME article in which he features heavily.

The good news is that he loves our project and the=data we showed him both in mouse and human models as well as the early data=on our own ongoing pancreatic cancer trial, so much so that he has agreed t= become our Chief Investigator for a new phase 3 trial in pancreas.

I think you will agree that this is a huge vote of=confidence in our project and especially as we will do this in the US. All t=at is needed is to fund the study and we would look for some \$10million - t=ere would be a lot of subsidy from Dan's group so this is a cheap study for a phase3 pancreas. The r=mifications would extend to many other cancers as well as to the inflammato=y brain disorders which include Alzheimer's etc. This is very something wit= which your group could help.

In any case, we are delighted and our share price,=were we a public company, would certainly have risen nicely this week=

I hope you agree that our valuation is perhaps not so=daft as it sounds and there is room for more growth. Certainly, shares in a=l the companies that have immunotherapy in their portfolio have done very w=ll recently and especially Celgene and BMS, and it is highly likely that there will be a collaboration with us=and Celgene.

We will arrange to meet up but the next couple of wee=s are silly as we need to consolidate on the trip and plot our strategy and=not least raise the funds - the £9million I want will cover this nice= and I am confident I will get it.

Let's speak in a couple of weeks and fix a date to me=t up?

Yours aye

Charles

Charles Akle
BSc MS FRCS
London Clinic Cancer Centre - B2
22 Devonshire Place
London
W1G 6JA

T: [REDACTED]

M: [REDACTED]

F: [REDACTED]

This email message (including any documents, files, or previous email messages embedded in it or attached to it) is intended only for designated recipients. Some or all of the information may be confidential and not intended for public dissemination. If you have received the message in error please notify the sender and then delete the full content from your system without reading it. Unauthorised use, copying, printing, distribution or reproduction of the information contained in or attached to this message is not permitted.

<tn.jpeg>

=/html>=